Advertisement

Non-specific binding of [18F]FDG to calcifications in atherosclerotic plaques: experimental study of mouse and human arteries

  • Iina Laitinen
  • Päivi Marjamäki
  • Merja Haaparanta
  • Nina Savisto
  • V. Jukka O. Laine
  • Sanna L. Soini
  • Ian Wilson
  • Pia Leppänen
  • Seppo Ylä-Herttuala
  • Anne Roivainen
  • Juhani Knuuti
Original article

Abstract

Purpose

[18F]FDG has been used as an inflammation marker and shown to accumulate in inflammatory atherosclerotic plaques. The aim of this study was to investigate the uptake and location of [18F]FDG in atherosclerotic plaque compartments.

Methods

The biodistribution of intravenously administered [18F]FDG was analysed in atherosclerotic LDLR/ApoB48 mice (n=11) and control mice (n=9). Digital autoradiography was used to detect the ex vivo distribution in frozen aortic sections. In vitro binding of [18F]FDG in human atherosclerotic arteries was also examined.

Results

The uptake of [18F]FDG was significantly higher in the aorta of atherosclerotic mice as compared with the control mice. Autoradiography of excised arteries showed higher [18F]FDG uptake in the plaques than in the healthy vessel wall (mean ratio ±SD 2.7±1.1). The uptake of [18F]FDG in the necrotic, calcified sites of the advanced atherosclerotic lesions was 6.2±3.2 times higher than that in the healthy vessel wall. The in vitro studies of human arterial sections showed marked binding of [18F]FDG to the calcifications but not to other structures of the artery wall.

Conclusion

In agreement with previous studies, we observed [18F]FDG uptake in atherosclerotic plaques. However, prominent non-specific binding to calcified structures was found. This finding warrants further studies to clarify the significance of this non-specific binding in human plaques in vivo.

Keywords

Atherosclerosis PET [18F]FDG Plaque Calcification 

Notes

Acknowledgements

This work was funded by the Ida Montin Foundation, the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Paulo Foundation and the Hospital District of Southwest Finland.

The authors would like to thank Sanna Suominen, Tarja Marttila, Hannele Ylipahkala and Mervi Oikonen for technical assistance.

References

  1. 1.
    Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481–3488PubMedCrossRefGoogle Scholar
  2. 2.
    Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, et al. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004;45:1245–1250PubMedGoogle Scholar
  3. 3.
    Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708–2711PubMedCrossRefGoogle Scholar
  4. 4.
    Veniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J Clin Invest 1998;102:1559–1568PubMedGoogle Scholar
  5. 5.
    Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235–238PubMedGoogle Scholar
  6. 6.
    Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 2005;46:1278–1284PubMedGoogle Scholar
  7. 7.
    Ben Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med 2004;45:1816–1821PubMedGoogle Scholar
  8. 8.
    Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 2004;25:629–672PubMedCrossRefGoogle Scholar
  9. 9.
    Powell-Braxton L, Veniant M, Latvala RD, Hirano KI, Won WB, Ross J, et al. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 1998;4:934–938PubMedCrossRefGoogle Scholar
  10. 10.
    Veniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest 2000;106:1501–1510PubMedCrossRefGoogle Scholar
  11. 11.
    Leppänen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U, et al. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 2005;112:1347–1352PubMedCrossRefGoogle Scholar
  12. 12.
    Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004;55:503–517PubMedGoogle Scholar
  13. 13.
    Doherty TM, Uzui H, Fitzpatrick LA, Tripathi PV, Dunstan CR, Asotra K, et al. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J 2002;16:577–582PubMedCrossRefGoogle Scholar
  14. 14.
    Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982;34:285–290PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Iina Laitinen
    • 1
  • Päivi Marjamäki
    • 1
  • Merja Haaparanta
    • 1
  • Nina Savisto
    • 1
  • V. Jukka O. Laine
    • 2
  • Sanna L. Soini
    • 3
  • Ian Wilson
    • 4
  • Pia Leppänen
    • 5
  • Seppo Ylä-Herttuala
    • 5
  • Anne Roivainen
    • 1
  • Juhani Knuuti
    • 1
  1. 1.Turku PET CentreUniversity of TurkuTurkuFinland
  2. 2.Department of PathologyTurku University HospitalTurkuFinland
  3. 3.Department of Pharmacology and Clinical PharmacologyUniversity of TurkuTurkuFinland
  4. 4.Medical DiagnosticsGE Healthcare BiosciencesAmershamUK
  5. 5.A.I. Virtanen InstituteUniversity of KuopioKuopioFinland

Personalised recommendations